The burgeoning optimism surrounding classic psychedelics as revolutionary treatments for depression may need a recalibration, as emerging data suggests their efficacy might offer incremental, rather than transformative, gains for a significant portion of patients. This evolving understanding prompts a critical re-evaluation, drawing parallels to the trajectory of selective serotonin reuptake inhibitors (SSRIs) – once hailed as "wonder drugs" before real-world outcomes tempered the initial enthusiasm.
The SSRI Precedent: From Wonder Drug to Measured Efficacy
The narrative surrounding psilocybin mirrors, in many ways, the journey of SSRIs, particularly fluoxetine (Prozac). Introduced in 1987 after FDA approval, Prozac rapidly captured public and medical imagination. By 1989, New York magazine famously dubbed it a "wonder drug," and Newsweek followed suit in 1990, featuring the capsule on its cover and proclaiming it a "breakthrough for depression." This fervent reception was fueled by a prevalent hypothesis that depression stemmed from a simple "chemical imbalance" in the brain, which SSRIs and later SNRIs were purported to correct by increasing serotonin levels.
However, the scientific understanding of depression has evolved significantly. By 2023, a systematic review published in Molecular Psychiatry definitively concluded there was "no support for the hypothesis that depression is caused by lowered serotonin activity or concentrations." This scientific shift underscored a growing recognition that depression is a complex disorder with multifactorial origins, involving intricate neural circuits, genetic predispositions, environmental stressors, and psychosocial factors, rather than a singular neurochemical deficit.
The clinical record for SSRIs and SNRIs, when assessed in broader, real-world settings, proved more modest than initial pivotal trials suggested. The landmark Sequenced Treatment Alternatives to Relieve Depression (STARD) study, initiated in 2001 and publishing key findings around 2006, represented the largest real-world trial of antidepressant treatment to date. Enrolling 4,041 outpatients, STARD found that only about a third of patients (approximately 33%) achieved remission with their first antidepressant medication. For those who didn’t respond, subsequent treatment steps were often necessary, with remission rates dropping further for each successive treatment attempt. Overall, roughly two-thirds of patients required at least one additional medication, with remission rates reported at 28% on the clinician-rated Hamilton Depression Rating Scale (HAM-D17) and 33% on the patient-reported Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16) after the first step. This comprehensive study illuminated the chronic and often treatment-resistant nature of depression for a substantial portion of the patient population, highlighting the urgent need for more effective and durable therapeutic options.
Psilocybin’s Promising Dawn and the Rise of Hype
In recent years, classic psychedelics like psilocybin have been heralded as potential game-changers in psychiatry, particularly for conditions like treatment-resistant depression (TRD). The resurgence of psychedelic research, following decades of prohibition, was fueled by early-phase trials that reported remarkably high response and remission rates. For instance, a 2021 Johns Hopkins study involving 24 patients with major depression reported an impressive 71% response rate and 54% remission rate four weeks after just two psilocybin sessions. That same year, a head-to-head trial comparing psilocybin with the SSRI escitalopram indicated psilocybin’s response rate to be close to 70%, further fueling the narrative of a potentially superior treatment modality.
This initial wave of positive findings generated considerable excitement within the scientific community, among patient advocacy groups, and in the popular media. The unique mechanism of action of psilocybin—primarily through its agonism of serotonin 2A receptors, leading to transient alterations in perception and thought patterns often described as profound and therapeutic—offered a stark contrast to the daily regimen of SSRIs. The potential for rapid-acting, durable effects after only one or two supervised sessions presented an appealing alternative for patients struggling with chronic depression and the often-debilitating side effects of conventional antidepressants.
Real-World Data Emerges: A Sobering Look at Efficacy
As research into psilocybin progressed from smaller, tightly controlled trials to larger, more diverse patient cohorts and real-world clinical settings, a pattern of more modest efficacy began to emerge, echoing the earlier experience with SSRIs.
One of the most recent insights comes from a retrospective study conducted at the University Hospital of Psychiatry Zurich, published in The Lancet Regional Health – Europe. This study followed 19 patients with severe treatment-resistant depression who received psilocybin under Switzerland’s limited-medical-use exemption – a rare framework permitting the drug outside of a formal clinical trial. This "real-world" context is crucial, as it provides a glimpse into how the treatment might perform in typical clinical practice rather than under ideal research conditions.
The Zurich study observed a significant drop in depression scores, from approximately 31 to 20 on the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS), which statistically represents a large effect. However, the rates of response and remission were more tempered: about a third of patients (33%) responded to treatment, and a fifth (22%) achieved remission. The authors themselves noted that these figures reside at the lower end of the trial literature for psilocybin and are roughly comparable to the remission rates observed in the initial treatment step of the STAR*D study for SSRIs. Furthermore, the benefit appeared to be front-loaded, with the first psilocybin session yielding the most significant improvement, and repeat dosing adding little incremental gain that could be definitively separated from chance in the small sample size.
This pattern of "cooling" efficacy was also observed in larger industry-sponsored trials. Compass Pathways, a leading biopharmaceutical company focused on psilocybin therapies, conducted the largest Phase 2b trial for psilocybin (COMP360) in treatment-resistant depression. While initial results showed a response rate of approximately 37%, this figure declined to 20% by week 12, further indicating that the dramatic efficacy seen in earlier, smaller studies might not fully translate to broader populations and longer follow-up periods.
The pivotal Phase 3 trials conducted by Compass Pathways, designed to support regulatory approval, continued this trend. While both trials successfully met their primary endpoints—a single dose in 2025 and two doses in early 2026—the separation from the control group was modest, averaging about 3.6 and 3.8 points on the MADRS scale. Notably, the company utilized a 25% response threshold rather than the more conventional 50% threshold for defining clinical response, a decision that underscores the challenge of demonstrating large effect sizes in these complex patient populations. Despite these more conservative figures, Compass Pathways anticipates filing for FDA approval by the end of 2026, suggesting that even modest but statistically significant gains are considered valuable in the context of TRD.
Rotem Petranker, Ph.D., director of the Canadian Centre for Psychedelic Science, acknowledged the significance of these findings despite the tempered efficacy. "All the participants in this study had treatment-resistant depression, meaning nothing works," Petranker stated, emphasizing the profound need for any effective intervention. "Imagine any disorder where nothing works, where every treatment we can give you is palliative, and then something works, even if it doesn’t work for everyone. I think that’s pretty cool." His perspective highlights that even if psilocybin isn’t a universal cure, its potential to provide relief for a segment of TRD patients, who often have exhausted all other options, remains a vital advancement.
The Blinding Challenge and Methodological Rigor
One of the persistent methodological challenges in psychedelic research, which may contribute to the observed "cooling" of efficacy signals, is the difficulty of maintaining blinding. Patients receiving a psychedelic dose typically experience profound subjective effects, making it nearly impossible for them or their therapists to remain unaware of whether they received the active drug or a placebo. This "unblinding" can introduce a significant expectancy bias, where participants’ strong beliefs about the drug’s potential effects might influence their reported outcomes, potentially inflating early trial results.
This concern was notably articulated by psychiatry researchers Philip Harvey and Charles Nemeroff in a January 2026 review in Neuropsychopharmacology. They highlighted that the FDA’s rejection of MDMA-assisted therapy for PTSD (discussed below) included reasons "that could apply to clinical trials for classical psychedelics," specifically citing the inherent difficulty of blinding patients.
Two recent meta-analyses further illuminate this issue by directly comparing psychedelic efficacy under conditions of varying blinding. In JAMA Network Open, Hieronymus and colleagues found broadly similar active-arm response rates across psilocybin (48%), SSRIs (46%), and esketamine (52%). However, they noted that psilocybin control arms responded at a lower rate than SSRI or esketamine controls, suggesting a stronger distinction between active drug and placebo in psychedelic trials, which could be indicative of unblinding effects.
More strikingly, Williams, Barnett, and Szigeti, in a study published in JAMA Psychiatry, took an innovative approach by treating psychedelic-assisted therapy trials as functionally "open-label" due to the unblinding issue, and then compared them with conventional open-label antidepressant trials. Across 24 trials, their analysis revealed that psychedelic-assisted therapy and open-label antidepressants produced nearly identical improvements on the 17-item Hamilton Depression Rating Scale, with only a marginal 0.3-point difference favoring antidepressants (95% CI, -1.39 to 1.98; P = .73). The authors concluded that, under conditions of equal unblinding, psychedelic-assisted therapy showed no significant advantage.
This finding surprised Szigeti, who admitted to UCSF, "What I wanted to show is that even if you compare psychedelics to open-label antidepressants, psychedelics are still much better. Unfortunately, what we got is the opposite result, that they are the same, which is very surprising given the enthusiasm around psychedelics and mental health." This meta-analysis serves as a critical reminder of the need for rigorous methodology and cautious interpretation, especially when dealing with treatments that elicit strong subjective experiences and high patient expectations.
The MDMA Cautionary Tale: Navigating Regulatory Hurdles
The journey of MDMA-assisted therapy for PTSD offers a stark cautionary tale for the broader psychedelic movement and specifically for psilocybin’s path to market. Lykos Therapeutics, a company that emerged from the Multidisciplinary Association for Psychedelic Studies (MAPS), spearheaded the effort to gain FDA approval for MDMA-assisted therapy for post-traumatic stress disorder. Despite two positive Phase 3 trials, the FDA declined to approve the treatment in August 2024, requesting an additional Phase 3 trial. This decision led to significant corporate restructuring at Lykos, including substantial staff reductions.
Petranker views this outcome as largely foreseeable. "It was clear to everyone but MAPS that the FDA wouldn’t approve it, because their submission didn’t fit the requirements," he commented. A key issue was the integral role of intensive psychotherapy bundled with MDMA administration. Unlike a conventional drug where efficacy can be isolated, MDMA’s therapeutic effect is believed to be inextricably linked to the guided psychotherapeutic process. The FDA’s challenge lies in regulating a "package deal" that combines a drug with a complex, variable psychological intervention. Petranker noted, "MDMA won’t work on its own; it requires a psychotherapy component." This raises questions about standardization, training, and the distinct regulatory pathways for drugs versus therapies.
Furthermore, the unblinding issue, as highlighted by Harvey and Nemeroff, was a significant factor. The profound subjective effects of MDMA make placebo control extremely challenging, and the FDA expressed concerns about the integrity of the trial data under these conditions. The MDMA experience serves as a crucial lesson for companies like Compass Pathways, prompting them to "cross their t’s and dot their i’s" to ensure their submissions align perfectly with regulatory expectations.
A Relative Paucity of Psychedelic Data
Despite the intense interest, the sheer volume of data on psychedelic treatments remains significantly smaller compared to conventional antidepressants. Petranker pointed out, "Over the last 20 years, something like 1,500 people have been administered psilocybin in a clinical trial setting. Really not that many." To put this into perspective, the STAR*D trial alone evaluated approximately 2,900 patients in its first treatment step, out of over 4,000 enrolled. This limited dataset underscores the need for continued, extensive research to build a robust evidence base.
Petranker, a self-proclaimed skeptic, has consistently advocated for "rigorous, slow science." Six years ago, he published a paper urging the field to temper its enthusiasm, warning, "you’re writing checks you won’t be able to cash." He anticipated that the initially high response rates seen in smaller trials would shrink as studies grew larger and moved closer to real-world conditions. "The 50 or 60 percent response rates we’ve seen in some clinical trials? I’m very skeptical of those. If you look at SSRI trial results, the effects there are much bigger than what you see in real life," he explained. "It probably has something to do with the placebo response. People are very optimistic, there’s a lot of expectancy."
Microdosing: Another Bubble of Expectancy?
Petranker’s skepticism extends to the realm of microdosing, the practice of taking sub-perceptual doses of psychedelics. He was once more hopeful, noting in a 2020 interview that survey data suggested microdosers "fare better than people who don’t," with reported gains in mood, focus, and creativity.
However, further rigorous investigation has tempered this optimism. In what has been described as the largest randomized trial of psilocybin microdosing for depression, Petranker’s team administered two milligrams of psilocybin—a fraction of a standard dose—to participants. The results, detailed in a preprint published earlier this year, showed that both the drug and placebo groups improved. Moreover, more than half of the participants correctly guessed which arm they were in, again raising concerns about unblinding and expectancy effects. The clearest signal appeared not on traditional depression scales but on a measure of dysfunctional attitudes. Reflecting on these findings, Petranker stated, "I used to think a dose so small it’s unnoticeable could still be effective. I don’t really think that anymore." This shift in perspective highlights the importance of empirical data over anecdotal evidence or widespread cultural narratives.
Implications for Psychiatric Practice and Future Research
The evolving data on psilocybin suggests a future where these compounds will likely become a valuable, albeit not miraculous, addition to the psychiatric toolkit. While they may not achieve the initial "transformative" outcomes predicted by some, their unique mechanism of action and potential for helping patients with treatment-resistant depression—a population desperately in need of new options—cannot be overstated.
Sandeep Nayak, who directs the Johns Hopkins Center for Psychedelic and Consciousness Research, maintains a positive outlook despite the moderated Phase 3 results, anticipating that psilocybin treatment will clear the FDA, citing trial design and durability data as key factors. This perspective reflects a broader sentiment within the field: that even if psilocybin’s efficacy isn’t dramatically superior to existing treatments for all patients, its distinct profile and potential for sustained benefits after infrequent dosing could offer significant advantages for specific patient subgroups.
The path forward demands continued, rigorous scientific inquiry, moving beyond the initial hype to understand precisely who benefits most from psychedelic-assisted therapy, under what conditions, and for how long. It also necessitates addressing the complex logistical and regulatory challenges, particularly concerning the integration of psychotherapy and the management of patient expectations. As Petranker aptly summarized, the field is transitioning "from the very large, bombastic statements, ‘we’ve cured depression, this is it,’ to ‘this is a new tool we’ll use in the psychiatric toolbox.’" This measured approach promises a more sustainable and evidence-based integration of psychedelics into mainstream mental healthcare, offering hope without overselling the miracle.
